Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY20 results · Jul–Sep 2019
Natco Pharma reported revenue from operations of ₹485.70 crore (down 10.6% from Q2 FY19) and net profit of ₹117.70 crore (down 35.2% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 485.70 | 543.50 | −10.6% | 492.30 | −1.3% |
| Other income | 33.20 | 40.00 | −17.0% | 21.00 | +58.1% |
| Total income | 518.90 | 583.50 | −11.1% | 513.30 | +1.1% |
| Profit before tax | 139.40 | 235.30 | −40.8% | 183.80 | −24.2% |
| Net profit for the period | 117.70 | 181.60 | −35.2% | 142.80 | −17.6% |
| Attributable to shareholders of the company | 119.00 | 182.50 | −34.8% | 143.20 | −16.9% |
| EPS, basic (₹) | 6.55 | 9.89 | −33.8% | 7.87 | −16.8% |
| Net margin (%) | 24.2 | 33.4 | 29.0 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 457.70 | 522.40 | −12.4% | 464.70 | −1.5% |
| Other income | 33.90 | 39.70 | −14.6% | 20.40 | +66.2% |
| Total income | 491.60 | 562.10 | −12.5% | 485.10 | +1.3% |
| Profit before tax | 143.60 | 246.80 | −41.8% | 188.30 | −23.7% |
| Net profit for the period | 122.20 | 193.10 | −36.7% | 147.70 | −17.3% |
| EPS, basic (₹) | 6.72 | 10.47 | −35.8% | 8.11 | −17.1% |
| Net margin (%) | 26.7 | 37.0 | 31.8 |
Consolidated
- Filed with BSE
- 12 Nov 2019, 17:11 IST
- Board meeting
- 12 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2019, 17:11 IST
- Board meeting
- 12 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE